Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.
Studies into the pathophysiology of schizophrenia have consistently demonstrated a dysfunction of dopamine (DA) system regulation in this disorder. This includes hyper-responsivity to DA agonists, the therapeutic efficacy of DA antagonists, and augmented striatal DA release in response to amphetamine. Nonetheless, there is little evidence for a pathological alteration with the DA system itself in schizophrenia. Instead, it is suggested that the disturbance lies in the manner by which the DA system is regulated. Recently, rodent models of schizophrenia have been advanced based on developmental disruption that recapitulates many of the symptoms observed in human schizophrenia patients. We found that administration of the mitotoxin methylazoxymethanol acetate (MAM) to rats at gestational day 17 leads to adult rats that exhibit neuroanatomical, pharmacological, and behavioral characteristics consistent with schizophrenia. These rats also exhibit hyperactivity within the ventral subiculum of the hippocampus that corresponds to a loss of parvalbumin-containing interneurons. This hyperactivity causes an increase in the population activity of the DA neurons (i.e., more DA neurons are firing spontaneously), thus increasing the responsivity of the DA system to stimuli. When the ventral subiculum is inactivated, DA neuron population activity is restored to baseline, and the hyper-responsivity to amphetamine is normalized to that observed in control rats. These findings demonstrate a direct link between the hippocampal pathophysiology, interneuronal alterations, and hyperdopaminergic state observed in the schizophrenia patient. Moreover, this suggests an alternate pharmacotherapeutic approach based on the normalization of hippocampal activity in the treatment of schizophrenia in humans.
Lodge
Daniel J
DJ
Department of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Grace
Anthony A
AA
D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D005260:Female; D005865:Gestational Age; D006624:Hippocampus / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D008746:Methylazoxymethanol Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D009434:Neural Pathways / Q000502:physiology / Q000503:physiopathology; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000503:physiopathology; D051381:Rats; D012559:Schizophrenia / Q000503:physiopathology*; D015398:Signal Transduction / Q000502:physiology
D019384:Nucleic Acid Synthesis Inhibitors; D008746:Methylazoxymethanol Acetate; D004298:Dopamine